Jupiter Asset Management Ltd. Trims Stock Holdings in Catalyst Pharmaceuticals, Inc. $CPRX

Jupiter Asset Management Ltd. lowered its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 22.5% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 401,091 shares of the biopharmaceutical company’s stock after selling 116,575 shares during the quarter. Jupiter Asset Management Ltd.’s holdings in Catalyst Pharmaceuticals were worth $7,901,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Jones Financial Companies Lllp increased its holdings in Catalyst Pharmaceuticals by 14.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 4,061 shares of the biopharmaceutical company’s stock worth $79,000 after acquiring an additional 498 shares in the last quarter. Mission Wealth Management LP lifted its holdings in Catalyst Pharmaceuticals by 5.0% during the second quarter. Mission Wealth Management LP now owns 10,620 shares of the biopharmaceutical company’s stock valued at $230,000 after purchasing an additional 510 shares in the last quarter. Amalgamated Bank boosted its position in shares of Catalyst Pharmaceuticals by 2.0% in the second quarter. Amalgamated Bank now owns 32,619 shares of the biopharmaceutical company’s stock worth $708,000 after purchasing an additional 654 shares during the period. Huntington National Bank increased its stake in shares of Catalyst Pharmaceuticals by 105.0% in the second quarter. Huntington National Bank now owns 1,433 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 734 shares in the last quarter. Finally, HBK Sorce Advisory LLC raised its position in shares of Catalyst Pharmaceuticals by 6.9% during the 3rd quarter. HBK Sorce Advisory LLC now owns 11,958 shares of the biopharmaceutical company’s stock valued at $244,000 after purchasing an additional 768 shares during the period. 79.22% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 26,746 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $23.25, for a total transaction of $621,844.50. Following the sale, the director directly owned 2,360 shares in the company, valued at $54,870. This represents a 91.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Carmen Jeffrey Del sold 10,983 shares of the firm’s stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $23.33, for a total value of $256,233.39. Following the completion of the sale, the insider owned 3,962 shares of the company’s stock, valued at approximately $92,433.46. This represents a 73.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 10.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, November 7th. Wall Street Zen upgraded Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Sunday, November 16th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research note on Monday, December 29th. Finally, Citigroup increased their target price on Catalyst Pharmaceuticals from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $33.20.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX opened at $24.30 on Friday. The company’s fifty day moving average is $23.83 and its 200 day moving average is $22.08. The stock has a market capitalization of $2.99 billion, a PE ratio of 14.13, a P/E/G ratio of 0.81 and a beta of 0.74. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $19.05 and a fifty-two week high of $26.58.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).